Hepatology

A Japanese cohort study has identified distinct liver enzyme trajectories in early adulthood that are strongly associated with the risk of developing type 2 diabetes.

By broadening definition of success to include sustained low-level HBsAg with suppressed HBV DNA, we can recognize clinically meaningful responses that improve patient outcomes, even without full antigen clearance.

By reconstructing a fetal liver–specific niche, FLOs enable simultaneous development of hepatic and hematopoietic lineages, revealing cross-talk essential for understanding human liver development and immune injury.

AI-enhanced ECG screening uncovers silent liver cirrhosis, enabling earlier diagnosis and intervention in routine primary care.

A long-term study shows that recurrence beyond the Milan criteria, rather than recurrence itself, drives poorer survival after curative hepatocellular carcinoma resection.

Study shows DAAs and interferon offer similar long-term protection against hepatocellular carcinoma after hepatitis C cure and introduces a nomogram to predict 8-year HCC risk.

Phase II ELMWOOD trial shows elafibranor is well tolerated and improves liver biochemistry and pruritus in primary sclerosing cholangitis, supporting further trials.

A phase 2 trial finds tinengotinib demonstrates anti-tumour activity in previously treated advanced cholangiocarcinoma with FGFR alterations.